The p53 pro-apoptotic tumour suppressor is mutated or functionally altered in most cancers. In epithelial tumours induced by 'high-risk' mucosal human papilloma viruses, including human cervical carcinoma and a growing number of head-and-neck cancers 1 , p53 is degraded by the viral oncoprotein E6 (ref. 2). In this process, E6 binds to a short leucine (L)-rich LxxLL consensus sequence within the cellular ubiquitin ligase E6AP 3 . Subsequently, the E6/E6AP heterodimer recruits and degrades p53 (ref. 4). Neither E6 nor E6AP are separately able to recruit p53 (refs 3, 5), and the precise mode of assembly of E6, E6AP and p53 is unknown. Here we solve the crystal structure of a ternary complex comprising full-length human papilloma virus type 16 (HPV-16) E6, the LxxLL motif of E6AP and the core domain of p53. The LxxLL motif of E6AP renders the conformation of E6 competent for interaction with p53 by structuring a p53-binding cleft on E6. Mutagenesis of critical positions at the E6-p53 interface disrupts p53 degradation. The E6-binding site of p53 is distal from previously described DNA-and protein-binding surfaces of the core domain. This suggests that, in principle, E6 may avoid competition with cellular factors by targeting both free and bound p53 molecules. The E6/E6AP/p53 complex represents a prototype of viral hijacking of both the ubiquitin-mediated protein degradation pathway and the p53 tumour suppressor pathway. The present structure provides a framework for the design of inhibitory therapeutic strategies against oncogenesis mediated by human papilloma virus.
. b, Surface representation of E6 coloured for residues in atomic contact with p53 (light blue), e6ap (light green), and both p53 and e6ap (dark grey). E6N and E6C: N-and C-terminal zinc-binding domains; HL: helix linker. E6 molecules on the left side of a and b are in the same orientation.
C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C C Letter reSeArCH core domain (residues 94-292, named p53core from hereon) by gel filtration chromatography and isothermal titration calorimetry (dissociation constant K d = 22 μm) (Extended Data Fig. 3 and Extended Data Table 1 ). In vivo, this affinity of p53 for E6/E6AP is likely to be enhanced by avidity effects, since p53 is tetrameric and E6AP can form trimers 13 .
The E6/e6ap/p53core ternary complex raised several crystals diffracting up to 2.25 Å resolution using synchrotron radiation. This allowed structure determination by molecular replacement (Fig. 1a and Extended Data Table 2 ). The asymmetric unit of the crystal comprises two E6/e6ap/p53core heterotrimers, which contact each other mostly via MBP and display nearly identical structures except for the relative orientation of the MBP moieties (Extended Data Fig. 4 ). The structures of p53core and E6/e6ap observed in the heterotrimers are superimposable with previous structures of p53core and of E6/e6ap heterodimer, except for residues 1-8 of E6 and 10-12 of e6ap, which change conformation upon p53 binding (Extended Data Fig. 5 ). The similarities between the structures of the two heterotrimers in the crystal and previously solved structures of separate elements suggest that MBP does not significantly alter the overall conformation of the E6/e6ap/p53core complex.
In each heterotrimer p53core binds to a cleft, which is formed by the E6N and E6C domains and held in place by contacts tethering the domains to the e6ap peptide (Figs 1b and 2a ). The E6-p53 interface covers approximately 1,200 Å 2 . The C terminus of the e6ap peptide (residues 10-12, Extended Data Fig. 6a ) also lies proximal to p53core (Extended Data Fig. 6b ), but its structure is poorly defined, possibly owing to an influence of the adjacent MBP tag. Nevertheless neither point mutations at residues 10-12 of e6ap nor extension of the e6ap peptide's C-terminal boundary altered p53 binding affinity (Extended Data Fig. 6c and Extended Data Table 1 ), suggesting that the e6ap C terminus does not contribute significant intermolecular contacts to p53.
The E6-p53 interface can be divided into three sub-interfaces (Figs 1a and 2b). Sub-interface I is dominated by polar interactions and brings together residues in the N-terminal arm and α1 helix of E6 and residues of the N-terminal arm, β1 and β10 strands of p53core ( Fig. 2b, c ). E6 residues Glu7 and Glu18 establish a bi-dentate salt bridge with Lys101 of p53 as well as water-mediated interactions with other p53 residues. In particular, Glu18 contributes to a network involving side chains and backbone groups of Gln14, Arg10 and Lys11 of E6, and of Thr102 and Asn268 of p53. Consistently, E6 mutations E18A and E18R impair ternary complex assembly ( Fig. 3a ) and p53 degradation ( Fig. 3b ). Furthermore, Gln104 and Gly105 of p53 hydrogen bond to the backbone of E6 residues Arg8 and Gln6, respectively, thus altering the conformation of the N-terminal arm of E6 (residues 1-8) (Extended Data Fig. 5 ).
Sub-interface II mainly involves the α2 helix of the E6N domain and the α2 helix of p53core, interacting through hydrophobic, charged and polar contacts (Fig. 2b, c) . E6 residue Phe47 intercalates between p53 residues Ala129 and Arg290. In turn, Arg290 establishes a salt bridge with Asp44 of E6. These key interactions explain the reported dominant-negative phenotype of the E6 F47R mutant, which is defective for p53 degradation, restores high p53 levels and drives senescence 14 . Upper and lower case fonts: residues mediating polar interactions via side chain and backbone, respectively. c, Key interaction networks. Gold fonts: E6 residues; blue fonts: p53 residues; green boxed black fonts: e6ap residues; thick grey dashed lines: non-polar interactions; black lines: polar interactions involving side-chain groups; black dotted lines: polar interactions involving backbone groups; red circles: water molecules. 
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Consistently, here we find that E6 F47R is defective for interaction with both p53core (Extended Data Fig. 3a ) and full-length p53 ( Fig. 3a ). Besides Phe47, other E6 residues in sub-interface II (Ile23, His24 and Tyr43) provide hydrophobic contacts, whereas E6 residue Asp49 establishes polar interactions with His115 in the L1 loop of p53. Mutations disrupting the Asp44-Arg290 and Asp49-His115 interactions (D44R and D49A in E6 and the R290E in p53) impair both p53 ternary complex assembly ( Fig. 3a ) and p53 degradation ( Fig. 3b ). By contrast, creation of a swapped Glu290-Arg44 salt bridge, by combining D44R E6 and R290E p53 mutants, partly restores p53 degradation ( Fig. 3b ).
Finally, sub-interface III encompasses hydrophobic interactions between E6C residues Leu100 and Pro112 and p53core surface residues Leu114 and Trp146, as well as several water-mediated backbone-to-backbone contacts (Fig. 2b, c) . Notably, Leu100 and Pro112 of E6C are proximal to conserved Arg102, which shapes the p53 binding cleft by mediating crucial interactions with the E6N domain and the e6ap peptide 8 .
Degradation of p53 is a hallmark activity of hrm-HPV E6 proteins [15] [16] [17] . The structure explains the critical contributions towards p53 degradation of particular residues, which are differentially conserved in high-versus low-risk mucosal (lrm) HPV E6. In sub-interface I, most conserved positions in hrm-HPV E6 proteins correspond to Phe2, Pro5, Glu7, Arg8 and Pro9 ( Fig. 2a ). While Glu7 mediates direct contacts to p53, Phe2, Pro5, Arg8 and Pro9 play an indirect role at the interface by shaping the conformation of the N-terminal region (Extended Data Fig. 7 ). Indeed, sitedirected mutagenesis of Phe2, Pro5, Arg8 or Pro9 (refs 18-20) impairs ternary complex assembly and p53 degradation activities. In sub-interface II, most conserved positions in hrm-HPV correspond to Phe47, Asp44 and Asp49 ( Fig. 2a ), which are here found to mediate crucial contacts to p53. These residues were formerly found to be important for p53 degradation 14, 18, 21 . Notably, Phe47 and Asp44 also participate in the dimerization of the E6N domain and subsequent in vitro self-association of the entire E6 protein 12 .
Figure 3
| Ternary complex assembly and p53 degradation activities of E6 and p53 mutants. a, Triple pull-downs. E6AP, E6 and biotinylated p53 were co-expressed in HEK 293T cells. E6AP bound to p53 was detected by western blotting. All E6 mutations were introduced in the E6 4C/4S construct 12 . Asterisks indicate previously investigated mutants 12 . Top: instances of binding efficiencies. I: input; PD: pull-down. Bottom: percentage of E6AP bound to p53. See also Extended Data Fig. 8 . b, Assays for degradation of p53. Top: instances of degradation efficiencies showing p53 before and after incubation with 5 or 2.5 μl of E6 translation product. I 0 : p53 band at time = 0; I 2 h : p53 band at time = 2 h without E6 (see Methods). Bottom: p53 degradation activities with 2.5 μl of E6 product. The data (mean ± s.d.) were obtained from three independent experiments and normalized to 100% for the reference proteins (E6 4C/4S/WT p53). For gel source data see Supplementary Fig. 1 WT  N268D  R290E  I  I  I  PD  PD  PD   4C/4S  E18R  D49A   E6AP   a   b   I  I  I  PD  PD  PD  E6AP p53
Therefore, E6 self-association and E6 binding to p53 are two distinct and competing processes mediated by partly overlapping interaction surfaces.
The LxxLL peptide of E6AP is absolutely required for E6 binding to p53, yet it does not contribute significant contacts to p53. Furthermore, in the absence of the LxxLL motif of E6AP, the few interactions connecting E6N, linker helix and E6C should be insufficient to maintain the overall E6 architecture observed in the E6/e6ap heterodimer structure (see ref. 8 for further discussion). These observations indicate that the LxxLL motif structures the p53 binding cleft on E6, thereby rendering E6 competent for interaction with p53. Interestingly, we have shown that an in vitro selected peptide, targeting the LxxLL pocket of HPV-16 E6, induces recruitment of p53 to E6 (refs 22, 23) . Consequently, cellular proteins other than E6AP, which bind to the LxxLL pocket, might also promote the E6-p53 interaction.
The p53core is both a DNA binding domain and a protein-protein interaction hub. E6 interacts with the N-terminal arm of p53core and one of the edges of the β-sandwich. Previous mutagenesis studies had already suggested a role for these regions in E6 binding 9, 11, 24 . The E6-binding interface on p53core is distal from both the DNAbinding region and protein-binding surfaces observed in all other solved complexes of p53core (Fig. 4a ). Indeed, previously described protein-binding interfaces of p53core all overlap, albeit to different extents, with the DNA-binding region. In particular, the large T antigen (LTag) of oncovirus SV40, which does not degrade p53, buries the entire DNA binding interface of p53core, thereby inhibiting p53 trans-activation activity 25 . Consistent with these observations, two frequent cancer-associated mutations (R273C and R273L), affecting a prominent DNA-binding arginine residue of p53core, abolish binding to SV40 LTag, but do not alter the interaction with E6/E6AP 26 . Therefore, E6 might avoid competition with cellular factors by targeting both 'free' p53 as well as p53 bound to DNA or other proteins (Fig. 4b) . This, along with the irreversible character of the degradation process, renders E6 a potent inactivator of p53 functions. Supplementary Information is available in the online version of the paper.
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No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Preparation of protein samples. DNA constructs. Residues 403-414 of human E6AP (peptide sequence E 1 L 2 T 3 L 4 Q 5 E 6 L 7 L 8 G 9 E 10 E 11 R 12 ) were cloned via a three-alanine linker at the C terminus of a mutant MBP used to promote crystallization 8 . The point mutations introduced in MBP (D83A, K84A, K240A, E360A, K363A and D364A) have been previously described to increase the propensity of MBP to crystallize 29 . The E6 4C/4S mutant of HPV-16 (ref. 12) (named E6 from hereon) and the core (or DNA binding) domain of human p53 (residues 94-311) were cloned into the pETM-41 vector containing an N-terminal His 6 -MBP tag followed by a TEV cleavage site.
Protein expression and purification. MBP-e6ap, His 6 -MBP-tev-E6 and His 6 -MBP-tev-p53core constructs were overexpressed separately in Escherichia coli BL21(DE3) cells at 15 °C for 18 h. All constructs were purified separately by amylose affinity chromatography in buffer A (50 mM Tris pH 6.8, 400 mM NaCl, and 2 mM DTT). To remove soluble aggregates, all affinity purified samples were ultracentrifuged at 110,000 g in a swing SW41 rotor (Beckman) for 16 h at 4 °C. Hence p53core and E6 samples were digested by TEV protease. In the case of p53core, after TEV digestion samples were additionally purified on a heparin column. The resulting MBP-e6ap, E6 and p53 samples were thus concentrated and loaded separately onto a Superdex 75 HiLoad 16/60 gel filtration column (GE Healthcare) equilibrated in buffer A. All purification buffers were filtered, degassed and saturated with argon. Crystallization. The E6/e6ap/p53core complex was reconstituted by mixing MBP-e6ap and E6 and p53core samples in a 1:1:1 stoichiometric ratio in buffer B (50 mM Tris pH 6.8, 200 mM NaCl, 2 mM DTT, 5 mM maltose) and concentrated to 18 mg ml −1 before crystallization. Crystallization conditions were screened using commercially available kits (Qiagen, Hampton Research, Emerald Biosystems) by the sitting-drop vapour-diffusion method in 96-well MRC 2-drop plates (SWISSCI), employing a Mosquito robot (TTP Labtech). Initial crystals were obtained and used as seeds during further optimization steps.
After optimization, crystals (125 μm × 80 μm × 80 μm) grew in sitting drops made from 400 nl of protein solution at 18 mg/ml, 370 nl of reservoir solution containing 7.5% polyethylene glycol (PEG) 20 K, 50 mM MES (pH 6.5) and 30 nl of seeds. Drops were equilibrated against 50 μl of reservoir solution at 290 K. Crystals were sequentially transferred through two cryo-solutions of reservoir solution supplemented with 15% (v/v) and 25% (v/v) of PEG 200, respectively. The crystals were flash-cooled and stored in liquid nitrogen. Data collection and processing, and structure determination. X-ray diffraction data were collected on the X06DA beamline at the Synchrotron Swiss Light Source (Villigen, Switzerland). Data were acquired from a single cryo-cooled crystal (100 K) on a Pilatus-2M detector. The 200° data were collected up to a resolution of 2.25 Å using 0.5° rotation and 0.8 s exposure time with 20% beam attenuation for each image. The data were indexed, processed and scaled using HKL2000 (ref. 30 ). The crystals belonged to the monoclinic space group P2 1 with unit cell parameters a = 78.17 Å, b = 129.37 Å, c = 82.17 Å and β = 92.4°, with a refined crystal mosaicity of 0.28-0.34°. The asymmetric unit contained two copies of the E6/MBP-e6ap/p53core heterotrimer, with a corresponding Matthew's coefficient of 2.48 Å 3 per dalton and a solvent content of 50.34%. The structure was solved by two sequential molecular replacements using Phaser 31 and the structures of MBP, E6/e6ap complex and p53core as templates (PDB accession numbers 4GIZ and 1TUP, respectively). Crystallographic refinement involved repeated cycles of conjugate-gradient energy minimization and temperature-factor refinement, and was performed using PHENIX 32 followed by iterative model building in Coot 33 . All the disordered residues were fitted to the built electron density map, except from e6ap residue Arg12 in one of the two heterotrimers (corresponding to chain B residue Arg383 in the PDB file).
Data collection and refinement statistics are summarized in Extended Data Table 2 . The quality of the refined models was assessed using MOLPROBITY 34 . All molecular graphics figures were made using PyMOL 35 . E6 residues at interface regions (Figs 1b and 2a) were identified by the observation of an increase in solvent accessibility obtained upon removal of e6ap or p53core from the PDB file of the ternary complex. Positive 'change in exposure' values ( Fig. 2a ) indicate E6 residues in atomic contact with or p53.
The refined model and the structure factor amplitudes have been deposited in the PDB under accession number 4XR8. DNA constructs for triple pull-down and p53 degradation assays. HPV-16 E6 mutations were inserted in the background of the E6 4C/4S construct to prevent cross-linking of E6 molecules through intermolecular cysteine bridges. We have previously shown that E6 4C/4S and wild-type HPV-16 E6 have indistinguishable p53 degradation activities in vitro 12 . The p53 mutations were inserted in the background of wild-type full-length human p53. All DNA constructs were verified by sequencing. Triple pull-downs. DNA constructs encoding for full-length HPV-16 E6 and p53, and a large fragment of E6AP (residues 291-875 of isoform II), were inserted into the final destination vectors by Gateway cloning (Invitrogen). HPV-16 E6 and E6AP were inserted into the GPCA pSPICA-N2 and pSPICA-N1 vectors respectively. GPCA vectors pSPICA-N1 and pSPICA-N2 (both derived from the pCiNeo mammalian expression vector) allow expression of test proteins as fusions to the C terminus of Gluc1 and Gluc2 complementary fragments of the Gaussia princeps luciferase, respectively 36 . By contrast, p53 constructs were inserted in the BioEase-DEST vector 36 , which incorporates a 72-amino-acid sequence from Klebsiella pneumonia that directs in vivo biotinylation. Degradation assays. HPV-16 E6 and full-length p53 proteins were cloned in the pXJ40 vector. Triple pull-downs. HEK-293T cells were grown and maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% FCS and 50 μg ml −1 of gentamycin at 37 °C with 5% CO 2 and 95% humidity. Cells were seeded in six-well plates at a concentration of 3 × 10 5 cells per well. After 24 h, cells were transfected using JetPEI (Polyplus transfection) with 1 μg pSPICA-N2 plasmid expressing E6, 1 μg of pSPICA-N1 plasmid expressing E6AP protein and 1 μg of BioEase plasmid expressing p53. At 24 h after transfection, cells were harvested and lysed by freezethawing in 100 μl of Renilla lysis buffer (Promega, E2820). Cellular lysates were cleared by centrifugation at 11,000 g in a microfuge for 15 min at 4 °C. Subsequently, 30 μl of pre-equilibrated Streptavidin Mag Sepharose beads (GE Healthcare) were incubated with 60 μl of cellular lysate supernatant for 2 h at 4 °C, thereby allowing capture of biotinylated p53. Streptavidin beads were washed three times with TNE buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP40, 1 mM EDTA and protease inhibitor), resuspended with 25 μl of protein loading buffer and loaded on a 15% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gel. E6 and E6AP proteins were detected by western blotting using rabbit anti-Gluc antibody (NEB, reference E8023S), whereas p53 was detected using a mouse anti-p53 DO-1 antibody (Life Technologies, reference 13-4000). The immunoreactive bands were visualized using WesternBright Sirius (Advansta) and an LAS 4000 camera. Bands were quantified using ImageGauge software (Fujifilm). Error bars, s.d. from three independent experiments. Cell lines. The HEK-293T cell line was provided by P. Charneau. These cells were authenticated and tested to be mycoplasma free. p53 degradation assays. E6 and p53 proteins were in vitro translated in the presence of [ 35 S]methionine using the TNT T7 coupled rabbit reticulocyte system. The p53 degradation reactions were performed in 10 μl volumes by incubating 2 μl of p53 translation product with either 5 or 2.5 μl of E6 translation products at 28 °C for 2 h according to previously described protocols 2 . Reactions were resolved on a 15% SDS-PAGE gel. Gels were exposed to a PhosphorImager screen and scanned using a Typhoon FLA 9500 imaging system (GE Healthcare). Reactive p53 bands were quantified using ImageQuant TL software (GE Healthcare).
The p53 degradation activity values reported in Fig. 3 were derived using the formula (I 0 − I)/I 0 , where I is the intensity of the p53 double band after incubation with E6 and I 0 the p53 signal in the input lane. The p53 degradation activity values were normalized to 100% for the reference proteins (E6 4C/4S/WT p53). For p53 mutant proteins (Fig. 3b) , besides the I 0 input control, the I 2 h control (corresponding to p53 at time = 2 h in the absence of E6) was added to check for the intrinsic stability of p53 mutants. Error bars, s.d. from three independent experiments. Histograms report the average hydrodynamic radii of the particles, whereas error bars indicate size polydispersity. Numbers above the histograms indicate molecular mass estimates assuming a spherical model. This analysis shows that binding to MBP-e6ap enhances the solubility of E6, which, in the unbound state, displays a solubility threshold of 50 μM. However, in the case of E6/MBP-e6ap samples (grey histograms), particle size increases with raising concentration. By contrast, introduction of the F47R mutation in E6 (green histograms) stabilizes particle size to values close to what is expected for a simple heterodimer (∼60 kDa). Therefore we conclude that, despite the increase in solubility, E6/MBP-e6ap still undergoes weak self-association via the E6N region hosting Phe47 (see ref. 12 for further discussion). b, Gel filtration analysis of E6/ MBP-e6ap samples. The elution volumes for molecular size markers are reported on top of the figure. The expected elution volumes of a simple E6/MBP-e6ap heterodimer (1×, 60 kDa) and of a dimer of heterodimers (2×, 120 kDa) are indicated. Note the relative small shift in the elution volumes of the different samples compared with the differences in the hydrodynamic radii (a). This suggests that oligomers of the E6/MBP-e6ap heterodimer are rather weak and dissociate on the gel filtration column. See also Supplementary Methods.
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Extended Data Figure 4 | Comparison of the structures of the two E6/ MBP-e6ap/p53core heterotrimers (heterotrimers A and B) observed in the asymmetric unit. Green: e6ap fused to the C terminus of MBP (pink) via the AAA linker (red); gold: HPV-16 E6; blue: p53core; spheres: zinc atoms. a, Different orientation of MBP in the two heterotrimers, which results from the different conformations of the two AAA linkers. b, Superposition of the E6/e6ap/p53 regions of heterotrimers A (green/ gold/blue) and B (grey). The backbone r.m.s.d. for the E6/e6ap/p53 regions of the two heterotrimers was calculated by aligning backbone atoms of residues (1) 12-136 of HPV-16 E6, (2) 371-379 of e6ap and (3) 109-191 of p53core and found to correspond to 0.9 Å. Regions displaying significant differences are boxed. These regions are the ill-defined C-terminal region of the e6ap peptide (see also Extended Data Fig. 6 ) and the a4 helix of E6, which is not involved in the E6-p53 interface.
